Member Info for georgehume

It suggests that, when compared to existing therapies, SDC-1801 may offer patients a cleaner, more tolerable option in a proven therapeutic class. That is a compelling proposition, and it reinforces my conviction that SDC-1801 has genuine best-in-class potential.

As we approach the second half of the year, we remain confident in the prospects for our lead asset and excited about the benefits we believe we can bring to patients and investors.

Patience and faith are a powerful combination. ... :)

Oral administration of SAR-20347 at 50 mg/kg resulted in a significant amelioration of disease pathology, including reduced skin scaling and redness.[1] This clinical improvement was associated with a marked decrease in keratinocyte activation and a reduction in the levels of pro-inflammatory cytokines.

Treatment with SAR-20347 at a dose of 50 mg/kg led to a reduction in key cellular drivers of the disease. Specifically, a decrease in plasma cells, germinal center (GC) B cells, and T follicular helper (Tfh) cells was observed. These cell types are crucial for the production of autoantibodies and the overall pathogenesis of SLE.

CEPTOR.AI

10,761 followers

Introducing StratAI — an agentic decision engine for drug discovery built by RECEPTOR.AI.

Drug discovery is often managed as a linear funnel.

But in practice, every new result changes the program: the hypothesis, the priorities, the trade-offs, and the next best experiment.

StratAI helps discovery teams turn this complexity into an adaptive decision process.

It supports R&D decision-makers, medicinal chemists, and computational chemists in defining the starting strategy, building an evidence base, generating and evaluating hypotheses, planning computational and experimental workflows, and updating the path forward as new evidence appears.

The output is not just a ranked list or a piece of lab automation.

It is a clearer strategy for what to do next, why it matters, and how each new result should change the program.

StratAI is designed to support discovery across modalities, including small molecules, peptides, and biologics, as a shared decision layer within Receptor.AI’s PharmaSphere™ ecosystem.

Over the coming weeks, we’ll share short videos on StratAI architecture and practical discovery use cases.

First up: TYK2 — turning basic target context into a structured evidence base and actionable design hypotheses.

Learn more about StratAI in our News Release: https://lnkd.in/drJKkT7u

Listening to and rereading CC phrases like 'advancing business development discussions around our pipeline of assets' does imply that the Sareum is successfully jumping through the hoops of the Big Bio playbook! SP’s comment that they are 'advancing business development discussions around our pipeline of assets' carries significantly more weight after hearing the execs on the call. Apparently data is the key!

Dennis Rowland, CRL Managing Director, said:

"CRL's geological team are effectively working across multiple workstreams to deliver programme activities designed to generate high-quality datasets for inclusion in Redmoor's prefeasibility study. Further sampling of historical drill core and new infill drillholes are aimed at facilitating high-quality outputs and advancing geological confidence within parts of the Redmoor Mineral Resource with the objective of supporting the potential classification of Indicated Mineral Resources in the future."

"It is encouraging to see the deposit model accurately assisting in the identification of additional sampling zones from historic core, and laboratory results confirming the presence of mineralisation. These data will contribute directly to further model updates in due course."

"The project stands ready for another step-change in activities following successful receipt of planning permission for the expansion of the drilling programme. With further rigs due to arrive immediately after permissions are granted, we aim to progress a large and ambitious drill programme on a scale previously unseen in Cornwall."

Mark Burnett, Strategic Minerals' Executive Director, said:

"Redmoor continues to advance at pace and produce high-quality outputs. The team's efforts were recently recognised at the UK Mining Conference, where CRL won Exploration Discovery of the Year - recognising the exceptional results from the 2025 drilling programme, and Finance Deal of the Year - recognising the effective use of the 2025 grant funding award and the Company's ability to raise development funds. The Board has no doubt that the project will continue to produce results that demonstrate the scale and quality of the Redmoor deposit and the team developing it."

Hi All, Zeb up 30% today on publication. :)

... The next strategic pivot also involves mitigating the black box safety concerns of JAK inhibitors, effectively expanding the treatable patient pool while addressing the profound psychosocial burden of the condition...

Please can someone tell her to stop running and quickly change direction! 😂

Thanks - very excited at first glimpse for a micro-moment, as I thought strategic minerals were directly referenced! :)

Hi All, this was posted on SML by Propinquity. Sulpheric Acid: The Metals-versus-Food Paradox. Very relevant. Thanks

Https://x.com/ctindale/status/2055445243634577502

Hi All, Let's hope it's only the ICT with the issues and not the toxicity test! 🤞

Hi All, I bought in at 2.8p, then averaged up to 7p 😂 Still, thanks to all your well-informed posts, I'm still looking upwards. 😁😁😁

Near enough:

... That leaves the ex-China market dependent on a narrow set of restarts, expansions and development projects, including Tungsten West’s Hemerdon restart in the UK, Fireweed’s Mactung project in Canada, EQ Resources’ European operations, and smaller US and Australian projects ...

Date Time Trade Prc Volume Buy/Sell Bid Ask Value

20-Apr-26 11:43:30 7.14 1,574,453 Unknown* 6.80 7.00 112.42k

20-Apr-26 10:18:39 6.90 3,000,000 Unknown* 6.80 7.00 207.00k

20-Apr-26 14:02:00 6.90 2,000,000 Unknown* 6.80 7.00 138.00k

20-Apr-26 14:01:31 7.0185 1,823,673 Unknown* 6.80 7.00 127.99k

20-Apr-26 15:54:13 6.9013 662,804 Unknown* 6.80 7.00 45.74k

20-Apr-26 15:51:44 6.9979 714,479 Unknown* 6.80 7.00 50.00k

Apologies ... wrong board! :)

Sorry … £500000 …

Hi, The buyer of yesterday’s £50000 worth of late trades certainly agrees with you! 😀

The J.P. Morgan Healthcare Conference and the co-located Biotech Showcase are major venues for deal-making in the life sciences industry, known as the "birthplace of a lot of deals". Major transactions, including multi-billion dollar mergers and acquisitions (M&A) and licensing agreements, are frequently announced during the week of these events.

Historic & Notable Deals

The conferences consistently serve as a hub for significant M&A activity, with various years marked by substantial deal announcements.

2026 Conference (Upcoming)

The 2026 events (Jan 12–15 for JPM, Jan 12–14 for Biotech Showcase) are anticipated to have strong M&A interest, building on recent momentum. Companies like Samsung BioLogics and Celltrion are scheduled to present their growth and acquisition strategies.

2025 Conference

M&A was a dominant theme at the 2025 conference, with deals exceeding $18 billion announced during the week.

Johnson & Johnson's near-$15 billion acquisition of Intra-Cellular Therapies was the largest public biotech buyout in over a year.

Eli Lilly struck a deal worth up to $2.5 billion with Scorpion Therapeutics for access to an experimental cancer therapy.

GSK acquired IDRx for up to $1.15 billion to strengthen its oncology pipeline.

Gilead Sciences announced a $1.7 billion deal, including a $250 million upfront payment, for access to Leo Pharma's preclinical inflammation drugs.

2024 Conference

Dealmaking at the 2024 conference focused on strategic acquisitions, with two major deals announced:

GSK announced plans to buy antibody maker Aiolos Bio for up to $1.4 billion.

Johnson & Johnson acquired antibody-drug conjugate developer Ambrx for $2 billion.

2023 Conference

Building off strong momentum from the end of 2022, over $3.5 billion worth of deals were announced to coincide with the 2023 conference.

Chiesi's $1.25 billion acquisition of rare disease drugmaker Amryt Pharma.

AstraZeneca's $1.3 billion buyout of CinCor Pharma for treatments for hypertension and kidney disease.

A non-immunosuppressive? 🤞

Curtesy of the distribution and investor engagement teams !